Known as glucagon-like peptide-1 (GLP-1) receptor agonists, blockbuster drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, ...

It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug ...

Obesity has emerged as one of the most pressing public health challenges globally, affecting over 650 million adults, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is ...

Both partners have the right to advance new targets discovered under the deal, with reciprocal success milestones and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...

Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. The president-elect sued after George Stephanopoulos inaccurately ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...